What’s at stake: Grasslanz is hoping to echo its commercial success with endophytes with microbial bioprotectants and GMO research
Background: The commercialisation arm of Landcare Research has been profitable every year for more than 20 years without shareholder support and pays a dividend on request.
Main players: Grasslanz, AgResearch, John Caradus.
Investors are typically looking for the next big thing and it’s no different for AgResearch subsidiary Grasslanz.
It was set up more than 20 years ago to invest in developing plant and microbial technologies to add value to agriculture.
Grasslanz sits in the so-called valley of death between
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
What’s at stake: Grasslanz is hoping to echo its commercial success with endophytes with microbial bioprotectants and GMO research
Background: The commercialisation arm of Landcare Research has been profitable every year for more than 20 years without shareholder support and pays a dividend on request.
Main players: Grasslanz, AgResearch, John Caradus.
